The Latest Analyst Ratings for Revance Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Revance Therapeutics (NASDAQ:RVNC) in the last quarter. The average price target is $34.33, implying an upside from the current price of $13.81. However, this represents an 8.04% decrease from the previous average price target of $37.33.

September 20, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given bullish ratings for Revance Therapeutics, with an average price target of $34.33, indicating potential upside from the current price.
The bullish ratings from analysts indicate a positive outlook for Revance Therapeutics. The average price target of $34.33 is significantly higher than the current price of $13.81, suggesting potential upside. However, the decrease from the previous average price target suggests some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100